You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TNO155, spartalizumab, ribociclib, checkpoint inhibitor, SHP2, PD-1, CDK4/6, NSCLC, CRC, HNSCC, KRAS, esophageal SCC, GIST

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC Trial in Worldwide (TNO155, Spartalizumab,

Recruiting
  • Non-small Cell Lung Carcinoma
  • +4 more
  • Boston, Massachusetts
  • +8 more
Mar 18, 2022

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC Trial in Adelaide (BBP-398, sotorasib)

Recruiting
  • Solid Tumor, Adult
  • +3 more
  • Adelaide, South Australia, Australia
    Cancer Research SA
Aug 15, 2022

Head and Neck Squamous Cell Carcinoma Trial in Taipei (Ribociclib, Spartalizumab)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Taipei, Taiwan
    National Taiwan University Hospital
Apr 19, 2022

Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer Trial in United States (BMF-219)

Recruiting
  • Non Small Cell Lung Cancer
  • +16 more
  • Goodyear, Arizona
  • +10 more
Jan 24, 2023

Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

Recruiting
  • Advanced Breast Cancer
  • The combination of Dalpiciclib with physician-selected endocrine therapy
  • Chemotherapy selected by the physician
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)

Recruiting
  • Esophagus Squamous Cell Carcinoma
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023

Oesophageal Adenocarcinoma, Gastric Adenocarcinoma Trial in France (Capmatinib, Spartalizumab)

Suspended
  • Oesophageal Adenocarcinoma
  • Gastric Adenocarcinoma
  • Besançon, France
  • +6 more
Feb 1, 2023

Non Small Cell Lung Cancer Trial in Bayonne, Bordeaux, Pau (ICI treatment discontinuation, ICI treatment continuation)

Recruiting
  • Non Small Cell Lung Cancer
  • ICI treatment discontinuation
  • ICI treatment continuation
  • Bayonne, France
  • +4 more
Jul 27, 2022

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

Not yet recruiting
  • Advanced Breast Cancer
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center
Jun 28, 2023

Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 25, 2023

Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors Trial in Israel (Selinexor 100 mg, Docetaxel,

Recruiting
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • +2 more
  • Selinexor 100 mg
  • +6 more
  • Ashdod, Israel
  • +10 more
Jan 30, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023

NSCLC Trial in Worldwide (JDQ443, docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Caba, Buenos Aires, Argentina
  • +34 more
Dec 19, 2022

Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy Trial in Taipei City, Taipei (Palbociclib, Ribociclib,

Recruiting
  • Breast Cancer
  • +2 more
  • Taipei City, Taiwan
  • +1 more
Mar 15, 2023

Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

Not yet recruiting
  • Esophagus Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Nov 20, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Metastatic Breast Cancer, Breast Carcinoma Trial in United States (LEE-011, Fulvestrant, Placebo)

Active, not recruiting
  • Metastatic Breast Cancer
  • Breast Carcinoma
  • Birmingham, Alabama
  • +12 more
Feb 17, 2022

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

Completed
  • Non-small Cell Lung Cancer (NSCLC)
    • Nîmes, France
      Jean-Paul BEREGI
    Jan 25, 2023

    Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

    Recruiting
    • Breast Cancer
    • Wuhan, Hubei, China
      Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
    Nov 20, 2023

    Rectal Cancer Trial in Chongqing (CIETAI-R)

    Recruiting
    • Rectal Cancer
    • CIETAI-R
    • Chongqing, Chongqing, China
      Daping Hospital, Third Military Medical University
    Jul 21, 2023